Tandem Diabetes Care, Inc. (TNDM)

USD 33.0

(-3.59%)

Market Cap (In USD)

2.16 Billion

Revenue (In USD)

747.71 Million

Net Income (In USD)

-222.61 Million

Avg. Volume

1.55 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
21.85-53.69
PE
-
EPS
-
Beta Value
1.367
ISIN
US8753722037
CUSIP
875372203
CIK
1438133
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Devices
CEO
Mr. John F. Sheridan
Employee Count
-
Website
https://www.tandemdiabetes.com
Ipo Date
2013-11-14
Details
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.